CD274 and neoplasm: At present, there is currently no specific tumor vaccine that combines the two to target and kill tumor cells; therefore, our study is the first time to combine MUC1, PD-L1 and IgG1 Fc to prepare MUC1-Vax fusion protein and load it on DCs to prepare MUC1-Vax vaccine, which is different from the traditional tumor vaccine against MUC1 or anti-PD-L1 alone.